Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection

BACKGROUND: In phase 3 MODIFY I/II trials, bezlotoxumab significantly reduced recurrence of Clostridioides (Clostridium) difficile infection (rCDI) over 12 weeks. Choice of CDI antibacterial treatment may affect CDI-related outcomes; therefore, this prespecified analysis assessed if the magnitude of...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Open Forum Infect Dis
Päätekijät: Dubberke, Erik R, Gerding, Dale N, Kelly, Ciarán P, Garey, Kevin W, Rahav, Galia, Mosley, Audrey, Tipping, Robert, Dorr, Mary Beth
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2020
Aiheet:
Major Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7264839/
https://ncbi.nlm.nih.gov/pubmed/32523972
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa157
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia